transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).

Författare och institution:
Johan Svensson (Institutionen för invärtesmedicin); John-Olov Jansson (Institutionen för invärtesmedicin); Malin Ottosson (Institutionen för invärtesmedicin); Gudmundur Johannsson (Institutionen för invärtesmedicin); M R Taskinen (-); Olov Wiklund (Institutionen för invärtesmedicin); Bengt-Åke Bengtsson (Institutionen för invärtesmedicin)
Publicerad i:
The Journal of clinical endocrinology and metabolism, 84 ( 6 ) s. 2028-33
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
Obesity is associated with blunted GH secretion and an unfavorable lipoprotein pattern. The objective of this study was to investigate the effects of treatment with the oral GH secretagogue MK-677 on lipoproteins in otherwise healthy obese males. The study was randomized, double blind, and parallel. Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks. MK-677 treatment did not significantly change serum lipoprotein(a) [Lp(a)] levels. Serum apolipoprotein A-I and E (apoA-I and apoE) were increased at 2 weeks (P < 0.001 and P < 0.01 vs. placebo, respectively), but were not changed at study end. Serum total cholesterol and low density lipoprotein (LDL) cholesterol (LDL-C) levels were not significantly changed by MK-677 treatment. Serum high density lipoprotein (HDL) cholesterol (HDL-C) was increased at 2 weeks of MK-677 treatment (P < 0.01 vs. placebo), but not at 8 weeks. The LDL-C/HDL-C ratio was reduced after 8 weeks of MK-677 treatment (P < 0.05 vs. placebo). Mean LDL particle diameter was decreased at 2 weeks (P < 0.05 vs. placebo), but was unchanged compared with baseline values at 8 weeks (P = NS vs. placebo). The level of serum triglycerides was increased at 2 (P < 0.05 vs. placebo), but not at 8, weeks. Lipoprotein lipase activity in abdominal and gluteal sc adipose tissue was not affected by active treatment. In conclusion, treatment with the oral GH secretagogue MK-677 affected circulating lipoproteins. The effects on serum apoA-1, apoE, triglycerides, and mean LDL particle diameter were transient. At study end, the LDL-C/HDL-C ratio was decreased. MK-677 treatment did not significantly affect serum Lp(a) concentrations at the present dose and administration protocol.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin ->
Endokrinologi och diabetes ->
Adipose Tissue, drug effects, metabolism, Adult, Anti-Obesity Agents, administration & dosage, therapeutic use, Apolipoproteins A, blood, Cholesterol, LDL, blood, Diet, Double-Blind Method, Human Growth Hormone, blood, secretion, Humans, Indoles, administration & dosage, therapeutic use, Injections, Subcutaneous, Lipoprotein(a), blood, Lipoproteins, blood, Male, Middle Aged, Obesity, blood, drug therapy, Particle Size, Spiro Compounds, administration & dosage, therapeutic use, Triglycerides, blood
Postens nummer:
Posten skapad:
2015-11-30 13:15

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007